Nimbus Therapeutics is Drug Discovery in United States that focus on immune-inflammatory disorders business. Founded in 2009. They cover business area such as developer, computational chemistry platform, breakthrough medicine, drug development, metabolic disease, cancer, disorder, selective small molecule therapeutic, physician, such medicine.
2009
( 15 years old in 2024 )
Immune-inflammatory Disorders
-
130 Prospect Street
Suite 301
Cambridge, MA 02139
United States
Private
developercomputational chemistry platformbreakthrough medicinedrug developmentmetabolic diseasecancerdisorderselective small molecule therapeuticphysiciansuch medicine
* We use standard office opening hours in near Nimbus Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Nimbus Therapeutics is Drug Discovery business from United States that founded in 2009 (15 years old in 2024), Nimbus Therapeutics business is focusing on Immune-inflammatory Disorders.
Nimbus Therapeutics headquarter office and corporate office address is located in 130 Prospect Street Suite 301 Cambridge, MA 02139 United States.
Nimbus Therapeutics was founded in United States.
In 2024, Nimbus Therapeutics is currently focus on immune-inflammatory disorders sector.
Above is snippet of Google Trends for "immune-inflammatory disorders" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Nimbus Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
